• Curis’ third-quarter 2026 net loss widened 5% year over year to $8.12 million.
• No revenue was reported due to the sale of Erivedge royalties in the fourth quarter of 2025.
• Research and development expenses fell 13% year over year to $5.6 million, primarily due to lower employee-related costs.
• The TakeAim CLL study enrolled 12 patients, with initial data expected in December 2026.
• Existing cash and approximately $7.5 million in October private-placement net proceeds are expected to fund operations into the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611121601PR_NEWS_USPR_____NE96836) on November 12, 2026, and is solely responsible for the information contained therein.